These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
619 related articles for article (PubMed ID: 11048517)
1. [The new atherogenic plasma index reflects the triglyceride and HDL-cholesterol ratio, the lipoprotein particle size and the cholesterol esterification rate: changes during lipanor therapy]. Dobiásová M; Frohlich J Vnitr Lek; 2000 Mar; 46(3):152-6. PubMed ID: 11048517 [TBL] [Abstract][Full Text] [Related]
2. [AIP--atherogenic index of plasma as a significant predictor of cardiovascular risk: from research to practice]. Dobiásová M Vnitr Lek; 2006 Jan; 52(1):64-71. PubMed ID: 16526201 [TBL] [Abstract][Full Text] [Related]
4. Lipid levels and cardiovascular risk in elderly women: a general population study of the effects of hormonal treatment and lipid-lowering agents. Dupuy AM; Carrière I; Scali J; Cristol JP; Ritchie K; Dartigues JF; Gambert P; Ancelin ML Climacteric; 2008 Feb; 11(1):74-83. PubMed ID: 18202967 [TBL] [Abstract][Full Text] [Related]
5. Angiotensin-converting enzyme gene polymorphism, lipids, and apolipoproteins in menopausal women on hormone replacement therapy. Cubrilo-Turek M; Sertić J; Duraković Z Acta Med Croatica; 2001; 55(4-5):161-7. PubMed ID: 12398019 [TBL] [Abstract][Full Text] [Related]
6. [Atherogenic index of plasma is associated with carotid intima-media thickness in patients with type 2 diabetes mellitus]. Hu YM; Tian HM; Liu R; Chen X Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Sep; 35(5):696-8, 707. PubMed ID: 15460423 [TBL] [Abstract][Full Text] [Related]
7. [Effect of ciprofibrate on the endothelial dysfunction of patients with combined dyslipidemia]. Kovács I; Tarján J; Császár A Orv Hetil; 2001 Apr; 142(15):775-9. PubMed ID: 11367862 [TBL] [Abstract][Full Text] [Related]
8. Atherogenic lipoprotein profile in families with and without history of early myocardial infarction. Dobiásová M; Raslová K; Rauchová H; Vohnout B; Ptácková K; Frohlich J Physiol Res; 2001; 50(1):1-8. PubMed ID: 11300220 [TBL] [Abstract][Full Text] [Related]
9. Ciprofibrate treatment decreases non-high density lipoprotein cholesterol and triglycerides and increases high density lipoprotein cholesterol in patients with Frederickson type IV dyslipidemia phenotype. Bermúdez-Pirela V; Souki A; Cano-Ponce C; Bermúdez-Arias F; Mengual-Moreno E; Leal-Gonzalez E; Lemus-Antepaz M; de Bravo MC; de Díaz AA; de Pirela NL; Cano-Peñaloza R; Puche-Medina G; Arraiz N; Reyna-Villazmil N; Contreras F; Israili ZH; Valasco M Am J Ther; 2007; 14(2):213-20. PubMed ID: 17414592 [TBL] [Abstract][Full Text] [Related]
10. Prothrombotic and lipoprotein variables in patients attending a cardiovascular risk management clinic: response to ciprofibrate or lifestyle advice. Mikhailidis DP; Ganotakis ES; Spyropoulos KA; Jagroop IA; Byrne DJ; Winder AF Int Angiol; 1998 Dec; 17(4):225-33. PubMed ID: 10204653 [TBL] [Abstract][Full Text] [Related]
11. Differential effect of hormone therapy and tibolone on lipids, lipoproteins, and the atherogenic index of plasma. Christodoulakos GE; Lambrinoudaki IV; Economou EV; Papadias C; Panoulis CP; Kouskouni EE; Vlachou SA; Creatsas GC J Cardiovasc Pharmacol; 2006 Apr; 47(4):542-8. PubMed ID: 16680067 [TBL] [Abstract][Full Text] [Related]
12. Achievement of optimal combined lipid values in a managed care setting: is a new treatment paradigm needed? Sarawate CA; Cziraky MJ; Stanek EJ; Willey VJ; Corbelli JC; Charland SL Clin Ther; 2007 Jan; 29(1):196-209. PubMed ID: 17379061 [TBL] [Abstract][Full Text] [Related]
13. Risk determination of dyslipidemia in populations characterized by low levels of high-density lipoprotein cholesterol. Bersot TP; Pépin GM; Mahley RW Am Heart J; 2003 Dec; 146(6):1052-9. PubMed ID: 14660998 [TBL] [Abstract][Full Text] [Related]
14. A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia. Kostapanos MS; Milionis HJ; Filippatos TD; Nakou ES; Bairaktari ET; Tselepis AD; Elisaf MS Clin Ther; 2007 Jul; 29(7):1403-14. PubMed ID: 17825691 [TBL] [Abstract][Full Text] [Related]
15. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome. Yilmaz M; Biri A; Bukan N; Karakoç A; Sancak B; Törüner F; Paşaoğlu H Gynecol Endocrinol; 2005 May; 20(5):258-63. PubMed ID: 16019370 [TBL] [Abstract][Full Text] [Related]
16. Lipoprotein profile and prevalence of cardiovascular risk factors in urban Moroccan women. El ayachi M; Mziwira M; Vincent S; Defoort C; Portugal H; Lairon D; Belahsen R Eur J Clin Nutr; 2005 Dec; 59(12):1379-86. PubMed ID: 16118656 [TBL] [Abstract][Full Text] [Related]
17. Lipid and lipoprotein profile in physiological pregnancy. Lippi G; Albiero A; Montagnana M; Salvagno GL; Scevarolli S; Franchi M; Guidi GC Clin Lab; 2007; 53(3-4):173-7. PubMed ID: 17447654 [TBL] [Abstract][Full Text] [Related]
18. Relation of cholesterol esterification rate to the plasma distribution of high-density lipoprotein subclasses in normal and hypertensive women. Dobiásová M; Stríbrná J; Frohlich JJ Clin Invest Med; 1995 Dec; 18(6):449-54. PubMed ID: 8714788 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of etofibrate and gemfibrozil in combined hyperlipidaemia. Wolf HR Drugs Exp Clin Res; 1994; 20(3):109-13. PubMed ID: 7956717 [TBL] [Abstract][Full Text] [Related]
20. [Ciprofibrate in the treatment of combined hyperlipoproteinemia. Results in more than 600 patients from 23 centers in the Czech Republic]. Ceska R; Kvasnicka T; Haas T; Soska V; Vaverková H Vnitr Lek; 2000 Mar; 46(3):157-60. PubMed ID: 11048518 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]